Psoriatic Arthritis

Kavanaugh discussed priorities in the disease fields in the last year of research.

Ruderman discussed recent research examining treatment choices after failure.

This rheumatology month in review emphasizes new data and FDA actions.

A groundbreaking study reveals that combining ixekizumab and tirzepatide significantly improves outcomes for adults with psoriatic arthritis and obesity.

This rheumatology month in review emphasizes new data and impactful approvals.

The Q4 recap for rheumatology spotlights regulatory and clinical advances across rheumatic diseases.

The rheumatology year in review highlights FDA approvals and pivotal data readouts.

The asthma year in review highlights FDA approvals, data, and advances in 2025.

Explore five pivotal FDA decisions set for early 2026 that could transform specialty medicine and enhance treatment options across various conditions.

This rheumatology month in review emphasizes new data from the ACR Convergence.

In long-term follow-up of KEEPsAKE 1 and 2, risankizumab maintained joint, skin, pain, and axial responses in patients with PsA through 244 weeks.

Sonelokimab meets ACR50 primary endpoint in a phase 2 trial.

Stay updated with the latest healthcare breakthroughs, including FDA news, regulatory submissions, and evolocumab data for ASCVD, in this week's essential news roundup.

The approval makes guselkumab the first and only IL-23 inhibitor approved for these pediatric indications and was based on data from the phase 3 PROTOSTAR study.

Risankizumab shows significant and lasting improvements in psoriatic arthritis symptoms, addressing multiple disease domains and enhancing patient quality of life.

A new meta-analysis has contrasted the association between the 2 conditions against the general population, psoriasis, rheumatoid arthritis, and ankylosing spondylitis.

Combining golimumab with methotrexate reduced corticosteroid reliance and maintained efficacy in psoriatic arthritis.

In this feature, 3 experts discuss the management of 2 overlapping conditions: psoriasis and psoriatic arthritis.

DRESS-PS extension study shows patients maintaining low disease activity while gradually reducing TNF inhibitor doses over 24 months.

The APEX study presents the results of 2 dosing regimens of guselkumab (Q4W and Q8W) in biologic-naïve patients with psoriatic arthritis (PsA).

Guselkumab shows promise as the first IL-23 inhibitor to significantly reduce joint damage in active psoriatic arthritis.

New phase 3 trials reveal tildrakizumab 100mg significantly improves symptoms in active psoriatic arthritis, offering hope for effective treatment options.

Mease described his real-world experience with using bimekizumab in the clinic for treating PsA and AxSpA.

Conversely, influenza vaccine was associated with increased COVID-19 severity and hospitalizations in patients with inflammatory rheumatic diseases.

Bristol Myers Squibb's deucravacitinib shows promise as a safe, effective treatment for active psoriatic arthritis, pending FDA approval by March 2026.